Efficacy and safety of antibody-drug conjugate based therapy in locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis of emerging clinical evidence.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
631 patients, were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The findings confirm the compelling efficacy and manageable safety profile of ADCs in this setting, while also underscoring the need for further clinical trials to validate and refine personalized treatment strategies. [SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/PROSPERO/, identifier CRD 420251114022.
[INTRODUCTION] Locally advanced or metastatic urothelial carcinoma (la/mUC) is associated with poor prognosis and limited treatment options.
- 95% CI 0.43-0.92
- OR 3.33
- HR 0.63
- 연구 설계 meta-analysis
APA
Dai Y, Xiao C, et al. (2026). Efficacy and safety of antibody-drug conjugate based therapy in locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis of emerging clinical evidence.. Frontiers in immunology, 17, 1728521. https://doi.org/10.3389/fimmu.2026.1728521
MLA
Dai Y, et al.. "Efficacy and safety of antibody-drug conjugate based therapy in locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis of emerging clinical evidence.." Frontiers in immunology, vol. 17, 2026, pp. 1728521.
PMID
41953009
Abstract
[INTRODUCTION] Locally advanced or metastatic urothelial carcinoma (la/mUC) is associated with poor prognosis and limited treatment options. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach. While previous meta-analyses have shown the efficacy and safety of ADCs in UC, the rapid development of new ADC agents and combination therapies necessitates an updated and comprehensive evidence synthesis.
[MATERIALS AND METHODS] A comprehensive search was performed in PubMed, Embase, Cochrane Library, and Web of Science from inception to September 2025. Interested outcomes include overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AES). RoB 2.0, ROBINS-I tools and GRADE framework were used for quality assessment.
[RESULTS] A total of 30 studies (5 RCTs and 25 single-arm trails), involving 3,631 patients, were included. Network meta-analysis showed that, compared with standard therapy, enfortumab vedotin (EV) in combination with pembrolizumab significantly improved OS (HR = 0.63, 95%CI: 0.43-0.92), ORR (OR = 3.33, 95% CI: 1.65-6.74), and PFS (HR = 0.48, 95% CI: 0.41-0.57). The safety results indicate that the ADC agents have a higher incidence rate of ≥3AES. The analysis of single-arm trails revealed that bulumtatug fuvedotin combined with toripalimab achieved an ORR as high as 88% (95% CI: 73%-96%), while disitamab vedotin-based combination therapy showed the longest median OS.
[CONCLUSIONS] This study provides a comprehensive synthesis of the latest clinical evidence on ADC-based monotherapy and combination regimens for la/mUC. The findings confirm the compelling efficacy and manageable safety profile of ADCs in this setting, while also underscoring the need for further clinical trials to validate and refine personalized treatment strategies.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/PROSPERO/, identifier CRD 420251114022.
[MATERIALS AND METHODS] A comprehensive search was performed in PubMed, Embase, Cochrane Library, and Web of Science from inception to September 2025. Interested outcomes include overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AES). RoB 2.0, ROBINS-I tools and GRADE framework were used for quality assessment.
[RESULTS] A total of 30 studies (5 RCTs and 25 single-arm trails), involving 3,631 patients, were included. Network meta-analysis showed that, compared with standard therapy, enfortumab vedotin (EV) in combination with pembrolizumab significantly improved OS (HR = 0.63, 95%CI: 0.43-0.92), ORR (OR = 3.33, 95% CI: 1.65-6.74), and PFS (HR = 0.48, 95% CI: 0.41-0.57). The safety results indicate that the ADC agents have a higher incidence rate of ≥3AES. The analysis of single-arm trails revealed that bulumtatug fuvedotin combined with toripalimab achieved an ORR as high as 88% (95% CI: 73%-96%), while disitamab vedotin-based combination therapy showed the longest median OS.
[CONCLUSIONS] This study provides a comprehensive synthesis of the latest clinical evidence on ADC-based monotherapy and combination regimens for la/mUC. The findings confirm the compelling efficacy and manageable safety profile of ADCs in this setting, while also underscoring the need for further clinical trials to validate and refine personalized treatment strategies.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/PROSPERO/, identifier CRD 420251114022.
MeSH Terms
Humans; Immunoconjugates; Network Meta-Analysis as Topic; Carcinoma, Transitional Cell; Treatment Outcome; Antineoplastic Combined Chemotherapy Protocols; Urinary Bladder Neoplasms; Urologic Neoplasms; Neoplasm Metastasis; Antineoplastic Agents, Immunological
같은 제1저자의 인용 많은 논문 (5)
- Buccal Fat Pad Transplantation for Correction of Asian Upper Eyelid Depression: A Clinical Study.
- Unveiling a new SORBS2::BRAF fusion in papillary thyroid carcinoma: insights from molecular diagnostics.
- Strategic characterization of active pharmaceutical ingredients co-eluting impurities: Identification, enrichment and structural elucidation of an oxidized impurity from mobocertinib drug substance.
- Mangiferin in human disease: Multifaceted mechanisms and applications (Review).
- Elevated alpha-fetoprotein affects the long-term prognosis after hepatectomy in patients with hepatitis B-related intrahepatic cholangiocarcinoma.